Evidence map›Paper›PMID 25226518›Full record

ArticlePloS one2014

Radioimmunoimaging of liver metastases with PET using a 64Cu-labeled CEA antibody in transgenic mice.

Stefanie Nittka, Marcel A Krueger, John E Shively, Hanne Boll, Marc A Brockmann, Fabian Doyon, Bernd J Pichler, Michael Neumaier

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Antibody Targeted PET Imaging ofBioconjugate chemistry · 2020
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Stefanie NittkaInstitute for Clinical Chemistry, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Marcel A KruegerDepartment of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, University of Tuebingen, Tuebingen, Germany.
John E ShivelyDepartment of Immunology, Beckman Research Institute, City of Hope, Duarte, California, United States of America.
Hanne BollDepartment of Neuroradiology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Marc A BrockmannDepartment of Neuroradiology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Department of Diagnostic and Interventional Neuroradiology, University Hospital of the Rheinisch-Westfaehlische Technical University Aachen, Aachen, Germany.
Fabian DoyonDepartment of Surgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Bernd J PichlerDepartment of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, University of Tuebingen, Tuebingen, Germany.
Michael NeumaierInstitute for Clinical Chemistry, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
University Medical Centre Mannheim · DEHeidelberg University · DECity of Hope · USSiemens (Germany) · DESTZ eyetrial · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeColorectal cancer is one of the most common forms of cancer, and the development of novel tools for detection and efficient treatment of metastases is needed. One promising approach is the use of radiolabeled antibodies for positron emission tomography (PET) imaging and radioimmunotherapy. Since carcinoembryonic antigen (CEA) is an important target in colorectal cancer, the CEA-specific M5A antibody has been extensively studied in subcutaneous xenograft models; however, the M5A antibody has not yet been tested in advanced models of liver metastases. The aim of this study was to investigate the (64)Cu-DOTA-labeled M5A antibody using PET in mice bearing CEA-positive liver metastases. PROCEDURES: Mice were injected intrasplenically with CEA-positive C15A.3 or CEA-negative MC38 cells and underwent micro-computed tomography (micro-CT) to monitor the development of liver metastases. After metastases were detected, PET/MRI scans were performed with (64)Cu-DOTA-labeled M5A antibodies. H&E staining, immunohistology, and autoradiography were performed to confirm the micro-CT and PET/MRI findings.

resultsPET/MRI showed that M5A uptake was highest in CEA-positive metastases. The %ID/cm(3) (16.5% ± 6.3%) was significantly increased compared to healthy liver tissue (8.6% ± 0.9%) and to CEA-negative metastases (5.5% ± 0.6%). The tumor-to-liver ratio of C15A.3 metastases and healthy liver tissue was 1.9 ± 0.7. Autoradiography and immunostaining confirmed the micro-CT and PET/MRI findings.

conclusionWe show here that the (64)Cu-DOTA-labeled M5A antibody imaged by PET can detect CEA positive liver metastases and is therefore a potential tool for staging cancer, stratifying the patients or radioimmunotherapy.

Indexed as

AntibodiesCarcinoembryonic AntigenCopper RadioisotopesPositron-Emission TomographyRadioimmunodetectionAnimalsAntibodies, MonoclonalAntibody SpecificityCell Line, TumorColorectal NeoplasmsDisease Models, AnimalFemaleImmunoconjugatesLiver NeoplasmsMagnetic Resonance ImagingMiceAntibodiesAntibodies, MonoclonalCarcinoembryonic AntigenCopper RadioisotopesImmunoconjugatesRadiopharmaceuticals

Identifiers

PMID25226518
PMCPMC4165898
OpenAlexW2029302851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.